Chengdu Easton Biopharmaceuticals Co., Ltd.: history, ownership, mission, how it works & makes money

Founded in 2009, Chengdu Easton Biopharmaceuticals Co., Ltd. rapidly evolved into a high-tech developer and manufacturer of APIs and finished dosage forms-culminating in a landmark listing on the Shanghai STAR Market in September 2020-and by April 2021 had industrialized 26 high-end chemical drugs and 17 chemical material medicines, with 14 generics passing Quality Consistency Evaluation and five chemical material medicines registered in major markets (EU, Japan, US); the company is scaling capacity with a new ~166,000 m² site and a Phase I investment of about USD 80 million (operations due Q2 2025), maintains R&D spending above 16% of revenue historically, employs over 1,000 staff, is advancing 10 innovative drugs (two in clinical Phase I/II), and has diversified revenue streams-reporting 1.35 billion CNY in 2024 revenue (up 20.82% YoY) with net income of 238.23 million CNY (up 5.15% YoY)-while market metrics (circa late 2025) show roughly 9.99 billion CNY market cap, 174.35 million shares outstanding and a trailing P/E near 41.77, complemented by a strategic acquisition raising its indirect stake in Shanghai Chaoyang to 30.6818% to accelerate global expansion.

Chengdu Easton Biopharmaceuticals Co., Ltd. (688513.SS): Intro

• Founded in 2009 as a high-tech enterprise focused on R&D, production and sales of chemical raw materials, high-end chemical medicines, and biopharmaceuticals.
• September 2020: Listed on the Shanghai Stock Exchange STAR Market (ticker: 688513.SS).
• By April 2021: Industrialized 26 high-end chemical drugs and 17 chemical material medicines.
• Developed four first-generic drugs for the domestic market and achieved Quality Consistency Evaluation (QCE) approval for 14 generic drugs.
• International registrations/certifications: five chemical material medicines registered or certified in major markets (EU, Japan, USA).
• 2021: Initiated new manufacturing site construction (~166,000 m²); Phase I investment ~USD 80 million, commercial operation targeted Q2 2025.

• Publicly listed company on SSE STAR Market (688513.SS), with typical shareholders including institutional investors, management/shareholders, and public float.
• Governance follows Chinese listed-company norms: board of directors, supervisory board, and executive management teams accountable to shareholders and regulators.

• Mission: Advance high-end chemical and biopharmaceutical capabilities to supply safer, higher-quality medicines domestically and internationally.
• Strategic focus:
  • Scale industrialization of proprietary and generic APIs and formulations.
  • Quality consistency and regulatory alignment for domestic and export markets (QCE compliance and international registrations).
  • Capacity expansion via a large new manufacturing campus to support volume growth and export ambitions.

• R&D pipeline: chemistry-driven discovery and process development for APIs and generics; formulation and stability work for finished dosages.
• Scale-up: pilot plants → validation → industrialization (company reported 26 industrialized high-end chemical drugs and 17 material medicines by Apr 2021).
• Quality & regulatory: domestic QCE for generics (14 passed) and international certifications/registrations (5 in EU/Japan/US markets) to enable exports.
• Manufacturing footprint: existing plants plus new 166,000 m² campus (Phase I USD 80M) to increase capacity, lower unit costs, and meet GMP/ICH expectations.

• API and chemical raw-material sales to domestic and international pharmaceutical manufacturers.
• Finished-dose formulations and generic drug sales in China (including first-generic offerings) and export markets.
• Contract manufacturing and technology transfer services leveraging industrialized processes and regulatory approvals.
• Licensing or co-development deals for proprietary processes or formulations (potential given registered international products).

Chengdu Easton Biopharmaceuticals Co., Ltd. (688513.SS): History

• Market capitalization (late 2025): ~9.99 billion CNY
• Shares outstanding: 174.35 million
• Trailing P/E ratio: 41.77

• June 2025 acquisition: purchased stakes in affiliated Shanghai Chaoyang to bolster global strategy and innovation capacity.
• Transaction details: acquired 7.9545% equity from Wu Hanchao and 11.3636% from Qi Lijia, raising Easton's indirect equity in Shanghai Chaoyang to 30.6818%.
• Funding: acquisition financed from Easton's self-owned funds, underscoring internal liquidity and strategic commitment.

Chengdu Easton Biopharmaceuticals Co., Ltd. (688513.SS): Ownership Structure

• Core mission: deliver clinically-needed medicines globally with an emphasis on patient outcomes and trust.
• Therapeutic focus: anesthesiology & pain, cardiovascular, oncology, children's medicines, diabetes.
• Strategic product focus: high-end generics, small-molecule innovative drugs, biologics.

• Pipeline scale: 10 innovative drugs under development; two candidates have progressed into clinical trials (one in Phase I and one in Phase II); several biologics in preclinical studies.
• R&D intensity: R&D expenses accounted for more than 16% of total revenue in each year from 2017 through 2020, materially above typical industry averages.
• Innovation & internationalization: ongoing investments in new modalities and global regulatory/commercial readiness.

• Ownership composition typically includes founding shareholders and management, institutional investors, and the public float following STAR Market listing.
• Corporate governance emphasizes R&D-driven value creation, with board and management aligned to long-term clinical and commercial milestones.

Chengdu Easton Biopharmaceuticals Co., Ltd. (688513.SS): Mission and Values

• Mission: Industrialize innovative APIs and finished formulations to improve patient access to high‑quality medicines globally.
• Values: Quality compliance (EU/US GMP alignment), R&D-driven scalability, environmental and workforce safety (EHS), and global regulatory engagement.
• Workforce & Compliance: Employs over 1,000 staff across R&D, manufacturing, quality and commercial functions; operates GMP‑compliant facilities meeting EU/US GMP and EHS standards.

• API process development and synthetic route optimization to support cost‑effective, high‑yield manufacturing.
• cGMP production lines for capsules, tablets and injectable products with in‑house quality control and stability testing.
• Regulatory affairs and global registration teams managing submissions and post‑market compliance in EU, US, Japan and other markets.

• Cardiovascular / Anticoagulant: Apixaban.
• Oncology: Apalutamide, Bosutinib, Dacomitinib, Ibrutinib, Nilotinib HCL, Nintedanib, Relugolix, Ruxolitinib Phosphate.
• Neurology / Psychiatry: Bricaracetam, Lacosamide.
• Anti‑diabetic: Empagliflozin.
• International registration: Five chemical material medicines certified or registered in major markets (EU, Japan, US).

• API manufacturing and long‑term supply contracts with multinational pharma and generic companies (volume‑based revenue).
• Finished dosage contract manufacturing (tablets, capsules, injections) and private‑label supply agreements.
• Proprietary or co‑developed product launches once regulatory approvals are obtained in target markets, driving higher margin finished product sales.

• Bench chemistry → pilot plant scale‑up → process validation → commercial GMP production.
• Parallel regulatory strategy to secure dossiers and registrations in target markets, enabling export sales and higher ASPs (average selling prices) for registered products.
• Quality systems and batch traceability to meet global distributor and regulatory demands, supporting long‑term supply contracts.

Chengdu Easton Biopharmaceuticals Co., Ltd. (688513.SS): How It Works

• Core activities: API synthesis, FDF formulation (capsules, tablets, injections), quality control and regulatory submissions.
• Therapeutic coverage: cardiovascular, oncology, neurological, psychiatric and anti-diabetic areas.
• Strategic focus: high-end generics and proprietary/innovative pharmaceuticals to capture margin improvements and differentiated market positions.

• R&D and drug substance chemistry: medicinal chemistry teams develop scalable synthetic routes for APIs and conduct impurity control to meet international standards.
• Process development and scale-up: pilot to commercial-scale synthesis, with manufacturing capacity for multi-tonne API production and sterile injectable fill/finish facilities for FDFs.
• Regulatory and quality systems: GMP-compliant manufacturing, stability studies, dossier preparation and regulatory filings for CN, EU, JP and US registrations.
• Commercial and distribution: domestic hospital tenders, national distributors and targeted international partners for export.

• Product mix: balance of low-cost bulk API sales and higher-margin finished dosage forms (capsules, tablets, injectables).
• Therapeutic diversification: oncology and cardiovascular portfolios provide steady demand and pricing power.
• Geographic expansion: registrations and certifications in EU, Japan and US open tender, hospital and distributor opportunities overseas.
• Manufacturing scale and quality: GMP capacity and reliable supply reduce per-unit cost and support larger contracts.

• Listed entity: traded as 688513.SS on the STAR Market; subject to public reporting, corporate governance rules and disclosure requirements.
• Institutional/shareholder mix: combination of strategic investors, institutional funds and public float (specific holders vary by latest filings).
• Reinvestment policy: profits channelled into R&D, capacity expansion and registration activities to support growth and margins.

• Target high-end generics and innovative drugs to capture premium pricing and reduce commoditization risk.
• Pursue regulatory approvals overseas to diversify revenue and mitigate domestic tender cyclicality.
• Maintain integrated API-to-FDF capability to retain margin across the value chain.

Chengdu Easton Biopharmaceuticals Co., Ltd. (688513.SS): How It Makes Money

• Product sales: marketed high-end generics and approved biologics sold in domestic and selected international markets.
• Innovative drug development: milestone and royalty income from licensing deals and partnerships for small-molecule and biologic candidates.
• Contract services and tech transfer: manufacturing, CMO/CDMO services and technology transfer fees.
• Strategic investments: minority stakes and M&A to capture upside from portfolio synergies (e.g., partial stake in Shanghai Chaoyang).

• Market position & future outlook: With a market cap of ~9.82 billion CNY and a trailing P/E of 41.05 (as of 2025-12-17), Easton occupies a strong mid-cap position in China's pharma sector, supported by sustained R&D spending and portfolio diversification.
• R&D-led growth: R&D expenses >16% of revenue (2017-2020) fuel a pipeline focused on high-end generics, small-molecule innovative drugs and biologicals, creating multiple near- to mid-term commercialization paths.
• Internationalization & M&A: The partial acquisition of Shanghai Chaoyang strengthens access to overseas channels, technology and collaborative R&D, enhancing long-term revenue streams.
• Financial foundation: High R&D investment, recurring product sales and strategic asset stakes combine to support investor confidence (reflected in P/E) and position the company for sustained growth.